As PD-L1 and CD73 are both overexpressed in the tumor microenvironment (TME) and inhibiting CD73 has been shown to enhance anti-PD-L1 efficacy, dual-targeting of PD-L1 and CD73 has emerged as a feasible strategy in the oncolytic field.